A Texas immigration bill authorizing state officials to arrest and deport immigrants would have no chance of survival but for the “destabilization” of Supreme Court jurisprudence during the Trump administration, says Prof. Peter Spiro. “If we were asking this question five years ago, it would be ‘this is just political theater on Texas’ part, and there’s no way that this law is going to go into effect.” Read More

Carly P. Reilly delves into scholarship by Prof. Jonathan Lipson and co-author David Skeel whether Sullivan & Cromwell bears some culpability for the FTX collapse. Watch

Several Justices seemed skeptical about plaintiffs’ standing in a Supreme Court case challenging the FDA’s approval of mifepristone. Dean Rebouche says a dismissal on such grounds will likely not deter future litigation with different plaintiffs. Read More

The Supreme Court will hear arguments at the end of April about whether a federal emergency care law supersedes Idaho’s near-total abortion ban. Dean Rebouche and co-authors David S. Cohen and Greer Donley have filed a brief arguing that it does and calling on the Court to overrule Dobbs. Read More

As Sam Bankman-Fried is sentenced to 25 years for his role in the FTX collapse, Prof. Jonathan Lipson tells the Guardian that the actions of Sullivan & Cromwell may have “distorted the criminal case and hurt depositors and creditors.” Read More

New guidance from the US Judicial Conference intended to prevent judge-shopping in all civil cases won’t have much impact on patent litigation, says Prof. Paul Gugliuzza. He points to Texas’s Western District court, where new filings show “that the judge shopping story in patent law is far from over—it’s just entering a new chapter.” Read More

As Sam Bankman-Fried faces sentencing for his role in the FTX bankruptcy, Prof. Jonathan Lipson joins Michael Lewis to examine how the case highlights problems with the US bankruptcy system itself. Read More

As the Supreme Court considers a case about the FDA’s regulation of mifepristone, Dean Rachel Rebouche explains how the outcome could impact not just access to abortion care but the FDA’s authority to do its job. Read More

The Financial Times reports on forthcoming scholarship by Prof. Jonathan Lipson and co-author David Skeel that details what they call possible “ethical violations” by Sullivan & Cromwell that “appear to have reduced recoveries, even as they have enriched S&C” in the FTX bankruptcy. Read More

Dean Rachel Rebouche explains what’s at stake in a case currently before the Supreme Court over the FDA’s regulation of mifepristone, one of two drugs used in medication abortion. Read More